One-glance verdict
Not enough data
Fair value unavailable
Not enough cash-flow history to value this one with our method.
Fundamentals snapshot
Greenwich LifeSciences, Inc.
GLSI · NCM · Healthcare · Biotechnology
Current price
$15.32
52-week range
$7.78 - $34.10
Market cap
$224.87M
Balance sheet
Healthy
-216.81x Concerning
Net cash $8.88M. Interest coverage shows how many times profit covers the interest bill.
What stands out
0 Rewards
1 Risk
0 rewards · 1 risks
View details ↓What this company does
Greenwich LifeSciences, Inc.
Greenwich LifeSciences is developing new treatments for breast cancer, specifically a therapy called GP2 that aims to stop cancer from coming back. The company is in the important stages of testing its treatments on people, and its success depends on these trials showing the therapy works well and is safe.
How the company got here
Greenwich LifeSciences, Inc. started its journey in 2006, originally known as Norwell, Inc. The company underwent a name change to Greenwich LifeSciences, Inc. in March 2018, signaling a renewed focus on its core mission. It is a clinical-stage biopharmaceutical company, meaning it's in the process of testing its potential medicines in human trials before they can be approved for widespread use. The company is headquartered in Stafford, Texas, and has been dedicated to developing innovative cancer immunotherapies.
What it actually does
At its heart, Greenwich LifeSciences is working on ways to help the body's own immune system fight cancer. They are developing new types of treatments, called immunotherapies, that aim to train the immune system to recognize and attack cancer cells. Their main focus is on cancers that have a specific protein on their surface, known as HER2/neu. This approach is different from traditional treatments like chemotherapy, which directly attack cancer cells, by instead empowering the patient's body to do the fighting.
GP2
The company's primary focus is on a product candidate called GP2, which is a type of immunotherapy designed to prevent breast cancer from coming back after initial treatment. GP2 is a HER2/neu transmembrane peptide, which essentially means it's a small piece of the HER2/neu protein that the company believes can trigger an immune response. This treatment is currently in Phase III clinical trials, which are the final stage of testing to confirm its safety and effectiveness in a large group of patients before seeking regulatory approval.
FLAMINGO-01
Another key development is FLAMINGO-01, a clinical trial program designed to test the safety and effectiveness of another product candidate, GLSI-100. This program is specifically looking at patients with HER2-positive breast cancer, which is cancer that has high levels of the HER2/neu protein. FLAMINGO-01 is progressing through different phases of clinical trials, including Phase IIb and three Phase I trials, to gather more data on how well GLSI-100 works and if it's safe for patients.
What management is betting on now
Greenwich LifeSciences' management is heavily invested in advancing their lead product candidate, GP2, through its final stages of clinical testing. The success of the Phase III trials for GP2 is crucial, as it could lead to regulatory approval and the potential to offer a new way to prevent breast cancer recurrence for patients. They are also focused on gathering more data from the ongoing FLAMINGO-01 trials for GLSI-100, aiming to demonstrate its potential as a treatment for HER2-positive breast cancer.
Price history
How the share price has moved
—
Loading price history…
Earnings history
Last 8 quarters — what happened
Click any quarter to read the call summary and what the numbers say.
Revenue
—
Net income
$-3.95M
Diluted EPS
-0.27
Operating cash flow
$-1.94M
Free cash flow
—
Fetching…
Sources
Revenue
—
Net income
$-5.66M
Diluted EPS
-0.39
Operating cash flow
$-4.70M
Free cash flow
—
Fetching…
Sources
Revenue
—
Net income
$-7.92M
Diluted EPS
-0.58
Operating cash flow
$-3.17M
Free cash flow
—
Fetching…
Sources
Revenue
—
Net income
$-4.15M
Diluted EPS
-0.30
Operating cash flow
$-2.67M
Free cash flow
—
Fetching…
Sources
Revenue
—
Net income
$-4.03M
Diluted EPS
-0.30
Operating cash flow
$-2.23M
Free cash flow
—
Fetching…
Sources
Revenue
—
Net income
$-3.26M
Diluted EPS
-0.25
Operating cash flow
$-1.83M
Free cash flow
—
Fetching…
Sources
Revenue
—
Net income
$-8.04M
Diluted EPS
-0.62
Operating cash flow
$-1.85M
Free cash flow
—
Fetching…
Sources
Revenue
—
Net income
$-2.67M
Diluted EPS
-0.20
Operating cash flow
$-2.58M
Free cash flow
—
Fetching…
Sources
Is it cheap or expensive?
Fair value — vs current price $15.32
We couldn't calculate a fair value right now.
Is it drowning in debt?
Healthy
Net cash $8.9M - more cash than debt. Interest coverage -216.8x.
Net debt
$-8.88M
Interest coverage
-216.81x
Greenwich LifeSciences, Inc.'s profit covers its interest bill about 0.0 times over. which is weaker than most peers shown here and 4 peers sit below 1x, which is the danger zone where profit does not fully cover the interest bill.
Healthy
Worse cushion
Baseline
Better cushion
GLSI
BASELINE
Greenwich LifeSciences, Inc.
Total debt $0.00 Interest coverage -216.81x This is the baseline the peer rows are being compared against.
Total debt $112.32M Interest coverage -8.69x Neither company has much profit cushion over interest right now.
Total debt $24.82M Interest coverage -9,479.76x Neither company has much profit cushion over interest right now.
Total debt $30.41M Interest coverage -1,395.03x Neither company has much profit cushion over interest right now.
Total debt $11.24M Interest coverage -6.78x Neither company has much profit cushion over interest right now.
What you should know
The case for and against GLSI
0 Rewards
1 Risk
Rewards
Risks
-
Return on equity was -986.3% last year — the company lost money on shareholders' equity.
The numbers
All the key metrics, grouped by purpose
Tap any ? icon to learn what it means.
Valuation
How expensive the stock looks
P/E (TTM)
—
Forward P/E
-18.68x
P/B
72.26x
P/S
—
EV/EBITDA
-9.53x
PEG ratio
—
Profitability
How much profit each dollar creates
Gross margin
0.0%
Operating margin
0.0%
Net margin
0.0%
ROE
-986.3%
ROA
-236.0%
Health
Liquidity and balance-sheet strength
Debt / equity
—
Current ratio
1.54x
Quick ratio
1.54x
Total debt
$0.00
Total cash
$8.88M
Growth
How the business has been compounding
Revenue TTM
$0.00
Revenue 5Y CAGR
—
EPS TTM
-1.53
EPS 5Y CAGR
—
Cash flow
How much cash the business throws off
Operating CF TTM
$-12.49M
Free CF TTM
$-9.91M
FCF margin
—
Dividend
Shareholder payout
Yield
0.0%
Payout ratio
—
Last ex-div date
—